AEM 28

Drug Profile

AEM 28

Alternative Names: AEM-28; Apolipoprotein E mimetic

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator University of Alabama at Birmingham
  • Developer LipimetiX Development
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Peptides
  • Mechanism of Action Apolipoprotein B modulators; Apolipoprotein E agonists; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 26 Aug 2016 AEM 28 is available for licensing as of 29 Jul 2016. http://www.lipimetix.com/businessmodel.html
  • 25 Aug 2016 Phase-II development is ongoing in Australia
  • 14 Oct 2015 Capstone Therapeutics receives patent allowance for AEM 28 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top